X
KEY PRODUCTS
Details:
PNEUMOSIL® (pneumococcal polysaccharide conjugate vaccine – adsorbed, 10 Valent), a well-designed vaccine, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.
Lead Product(s): Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Pneumosil
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Gates Foundation
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 12, 2022
Mass Spectrometry-ASMS Conference
Not Confirmed
Contact SupplierDetails:
PNEUMOSIL® (Pneumococcal Conjugate Vaccine – adsorbed, 10 Valent), a well-designed vaccine with relevant serotypes, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.
Lead Product(s): 10 Valent Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Pneumosil
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Serum Institute of India
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 31, 2022
Mass Spectrometry-ASMS Conference
Not Confirmed
Contact SupplierDetails:
Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer patients in this region.
Lead Product(s): Triptorelin
Therapeutic Area: Oncology Product Name: Trelstar
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 01, 2022
Mass Spectrometry-ASMS Conference
Not Confirmed
Contact SupplierDetails:
The license under discussion would enable Aspen, using COVID-19 vaccine JNJ-78436735, drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine for sale to public sector markets in Africa.
Lead Product(s): Ad26.COV2.S
Therapeutic Area: Infections and Infectious Diseases Product Name: JNJ-78436735
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 30, 2021
Mass Spectrometry-ASMS Conference
Not Confirmed
Contact SupplierDetails:
The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.
Lead Product(s): Esomeprazole Magnesium
Therapeutic Area: Gastroenterology Product Name: Trustan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Acino Pharma AG
Deal Size: $119.4 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 22, 2021
Mass Spectrometry-ASMS Conference
Not Confirmed
Contact SupplierDetails:
Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy due to menopause.
Lead Product(s): Conjugated Estrogens
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cenestin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avion Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 12, 2020
Mass Spectrometry-ASMS Conference
Not Confirmed
Contact SupplierDetails:
Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.
Lead Product(s): Fondaparinux Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Arixtra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viatris
Deal Size: $757.2 million Upfront Cash: $310.4 million
Deal Type: Acquisition September 08, 2020
Mass Spectrometry-ASMS Conference
Not Confirmed
Contact SupplierDetails:
The acquisition strengthens Sandoz’s presence in the hospital channel by complementing the broad Sandoz portfolio and pipeline of hospital generic and biosimilar products in Japan like Lidocaine Hydrochloride.
Lead Product(s): Lidocaine Hydrochloride
Therapeutic Area: Neurology Product Name: Lidocaine HCl-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: $440.0 million Upfront Cash: $330.0 million
Deal Type: Acquisition January 31, 2020
Mass Spectrometry-ASMS Conference
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
